GlycoMimetics, Inc. (NASDAQ:GLYC – Get Free Report)’s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.24 and traded as low as $0.21. GlycoMimetics shares last traded at $0.22, with a volume of 321,600 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com assumed coverage on GlycoMimetics in a research report on Tuesday. They set a “sell” rating for the company.
Check Out Our Latest Research Report on GLYC
GlycoMimetics Stock Performance
Institutional Inflows and Outflows
An institutional investor recently raised its position in GlycoMimetics stock. Acadian Asset Management LLC increased its position in GlycoMimetics, Inc. (NASDAQ:GLYC – Free Report) by 61.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 534,753 shares of the biotechnology company’s stock after buying an additional 204,227 shares during the period. Acadian Asset Management LLC owned 0.83% of GlycoMimetics worth $150,000 at the end of the most recent quarter. Institutional investors and hedge funds own 75.19% of the company’s stock.
GlycoMimetics Company Profile
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Further Reading
- Five stocks we like better than GlycoMimetics
- What is MarketRankā¢? How to Use it
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- Top Stocks Investing in 5G Technology
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.